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predictive risk model for anxiety after
completion of treatment for early stage
breast cancer
Jenny Harris1* , Edward Purssell2, Victoria Cornelius3, Emma Ream1, Anne Jones4 and Jo Armes1Abstract
Objective: To develop a predictive risk model (PRM) for patient-reported anxiety after treatment completion for early
stage breast cancer suitable for use in practice and underpinned by advances in data science and risk prediction.
Methods: Secondary analysis of a prospective survey of > 800 women at the end of treatment and again 6months
later using patient reported outcome (PRO) the hospital anxiety and depression scale-anxiety (HADS-A) and > 20
candidate predictors. Multiple imputation using chained equations (for missing data) and least absolute shrinkage and
selection operator (LASSO) were used to select predictors. Final multivariable linear model performance was assessed
(R2) and bootstrapped for internal validation.
Results: Five predictors of anxiety selected by LASSO were HADS-A (Beta 0.73; 95% CI 0.681, 0.785); HAD-depression
(Beta 0.095; 95% CI 0.020, 0.182) and having caring responsibilities (Beta 0.488; 95% CI 0.084, 0.866) increased risk,
whereas being older (Beta − 0.010; 95% CI -0.028, 0.004) and owning a home (Beta 0.432; 95% CI -0.954, 0.078) reduced
the risk. The final model explained 60% of variance and bias was low (− 0.006 to 0.002).
Conclusions: Different modelling approaches are needed to predict rather than explain patient reported outcomes.
We developed a parsimonious and pragmatic PRM. External validation is required prior to translation to digital tool and
evaluation of clinical implementation. The routine use of PROs and data driven PRM in practice provides a new
opportunity to target supportive care and specialist interventions for cancer patients.
Keywords: Anxiety, Patient reported outcomes, Breast cancer, Predictive risk models, Cancer survivors, Supportive careIntroduction
Symptoms of anxiety are frequently reported in response
to breast cancer diagnosis and treatment [1]. Around 18–
33% of women will experience anxiety following diagnosis
of cancer [2, 3] and this may persist in 25% of women liv-
ing with and beyond breast cancer (hereafter referred to
as breast cancer survivors, BCS) two to four years after
diagnosis, and in 15% after five [4]. Whilst internationally© The Author(s). 2020 Open Access This article
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Full list of author information is available at the end of the articlethe importance of risk assessment for follow-up care is in-
creasingly recognized [5, 6], there has been few attempts
to identify those likely to experience late emotional and
psychological effects amongst the growing number of can-
cer survivors and little application of modern approaches
to data science and predictive risk modelling [7, 8]. In
many countries follow-up care has shifted away from spe-
cialist cancer settings towards self-care and community-
based services for BCS at low risk of cancer recurrence
and late effects (physical and psychological) [7]. Given
these changes, one approach to ensure psychosocial dis-
tress is assessed and addressed would be to use patient re-
ported outcomes (PRO) alongside routinely collected datais licensed under a Creative Commons Attribution 4.0 International License,
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risk of anxiety, and related conditions, long-term to fur-
ther tailor supportive care services.
Predictive risk models (PRMs) aim to predict the risk of
having or developing an outcome based on multiple vari-
ables [9]. To date studies using best practice approaches to
PRM development have primarily focused on developing
models for clinical outcomes [10]. PRMs have been devel-
oped and applied to inform screening, care and treatment
recommendation in areas as diverse as organ transplant-
ation [11], cancer [12, 13] and cardiovascular disease [14].
Development of a PRM of anxiety in BCS could be used to
enhance follow-up care through heightened clinical aware-
ness [10] [7]. However, although cancer policy identifies the
need to offer extra support for high risk conditions such as
anxiety [15, 16] as yet validated PRM stratification tools are
lacking [7] and so are not routinely used.
Factors predictive of anxiety after completion of breast
cancer treatment remain under-researched, use cross-
sectional data [8] and are inadequately assessed [15], with
little application of best practice guidance in the modelling
process [17] [9, 18]. Traditional approaches to regression
modelling focus on explaining phenomena rather than the
ability to generate robust predictions [9, 18, 19]. This is
common practice in psychosocial research where models
are typically developed based on stepwise methods or uni-
variate screening (typically including a variable in a model
if it reaches a certain threshold of probability) [19]. Whilst
such approaches attempt to reduce bias to obtain repre-
sentations of the underlying data, this can lead to overfit-
ting of the model to the data and reduce predictive
performance in new data [20, 21]. If the goal is developing
predictive risk models, statistical methods are required
that minimize the combination of bias and estimation
variance, occasionally sacrificing accuracy for improved
precision and utility [9, 19]. A robust and useable PRM is
generalizable, not overfitted to the data, and limits the
number of variables that are required to be collected in
routine practice [9, 19]. Applying robust methods to de-
velop data driven and powerful PRM for psycho-oncology
is paramount if we are to target on-going assessment and
support in survivorship to those at greatest risk.
This study aimed to develop a predictive risk model,
using principles of statistical learning to ensure robust-
ness, [17] to determine the probability of experiencing
anxiety in women with early stage breast cancer, to esti-
mate the model’s predictive performance and undertake
internal validation.
Methods
Study design
Secondary data analysis of a longitudinal cohort, the
Supportive Care Needs Study (SCNS) of people receiving
treatment with curative intent. This secondary analysisfocused on women diagnosed with breast cancer only
[22]. Ethical approvals were obtained as part of the ori-
ginal study.
Participants and procedures
Sixty-six cancer centres in England participated in the
SCNS during 2005. Eligible patients were: ≥18 years; able
to read English; undergoing curative treatment; women
diagnosed with breast cancer. Nurses recruited consecu-
tive eligible patients. Participants self-completed a postal
survey after their final treatment (T0), and 6 months
later (T1), with non-response reminders. Previously pub-
lished work suggests the sample was representative of
cancer centres in the UK [22].
Outcome measure
The PRO was Hospital Anxiety and Depression Scale
(HADS)-Anxiety (HADS-A) [23] total sub-scale score 6-
months after treatment completion (T1). HADS-A in-
cludes seven items to compute a total anxiety score
(range 0–21). In clinical practice HADS-A is widely used
as a screening tool and is both valid and reliable for
identifying symptoms of anxiety in cancer and other
clinical populations [24, 25].
Potential predictors
Selection of predictors for inclusion in the model was in-
formed by results from a systematic review [8], written
feedback from people with cancer contacted through a
patient advocacy group and an expert advisory group.
They provided feedback on potential ease of use in clin-
ical settings (e.g. are data routinely collected or easily ac-
cessible?) and patient views (e.g. is it acceptable?), an
important consideration if a PRM is to be implemented
in routine clinical practice [10]. An overview of candi-
date predictors considered in the model is provided in
Table 1. These included socio-demographic (age, marital
status, caring responsibilities, employment status, high-
est educational level, car ownership, housing tenure,
self-reported financial strain), psychological (prior poor
mental health as indicated by T0 HADS) and clinical
variables (comorbidities, disability, type of cancer treat-
ment, self-report of feeling sick, fatigue or pain). Several
pre-determined interactions based on previous evidence
were considered including symptoms (pain, fatigue and
depression) [26] and economic factors (economic status,
homeownership and financial strain) [27].
Statistical analysis
Continuous predictors including age, HADS-A and
HADS-Depression (HADS-D) were used to retain max-
imum predictive information [28] and for later transla-
tion of the tool into different clinical practices where
appropriate risk grouping can be determined [29]. No
Table 1 Sample characteristics
Candidate predictors N (%)a
Socio-demographic
Age:
19–51 years 250 (31.1)
52–59 years 192 (23.9)
60–65 years 150 (19.7)
66–71 years 109 (13.7)
72+ years 102 (12.7)
Mean age 58.0 (SD 11.5)
(range 27–88)
Missing 13 (1.6)
Marital status
Married or living with partner 590 (72.5)
Widowed 92 (11.3)
Divorced / Separated 84 (10.3)
Single 48 (5.9)
Missing 2 (2.3)
White British ethnicity 761 (93.6)
Missing 3 (0.4)
Lives alone 140 (17.4)
Missing 11 (1.4)
Housing tenure
Owner-occupier 694 (85.3)
Renting 104 (12.8)
Other 16 (2.0)
Missing 2 (0.3)
Have any caring responsibilities 227 (28.5)
Missing 19 (2.3)
Highest level of qualification
No formal qualification 286 (35.6)
A level or equivalent 97 (12.1)
GCSE/O Level 242 (30.1)
Degree/higher degree 178 (5.1)
Missing 13 (1.6)
Employment status
Working 268 (33.2)
On leave 130 (16.1)
Retired 329 (40.7)
Not working 81 (9.5)
Missing 8 (0.3)
Use of car or van 709 (87.0)
Missing 19 (2.3)
Clinical
Mean HADS-A (baseline) 6.5 (SD 4.2,
median 6.0, IQR 6.0)
Missing 14 (1.4)
Table 1 Sample characteristics (Continued)
Candidate predictors N (%)a
Mean HADS-D (baseline) 3.5 (SD 3.2,
median 3.0, IQR 4.0)
Missing 4 (0.8)
Moderate or severe need: feeling unwell 64 (8)
Missing 15 (1.8)
Moderate or severe need: lack of
energy/fatigue
164 (20.3)
Missing 8 (1.0)
Moderate or severe need: feeling pain 70 (8.7)
Missing 14 (1.7)
Longstanding comorbid illness 317 (39.2)
Missing 7 (0.9)
Cancer-related treatments
Chemotherapy 350 (64.6)
Missing 274 (33.6)
Radiotherapy 766 (96.6)
Missing 23 (2.8)
Hormone therapy 537 (69.3)
Missing 41 (5.0)
Outcome
Mean HADS-A b 6.8 (SD 4.4)
Missing 150 (18.4)
a Candidate predictor counts and percentages are for valid responses, except
for missing data which represents overall figure
b Values for MI data. Complete case values were mean 6.7 (SD 4.3, median 6.0,
IQR 7.0)
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HADS questionnaire, so a pragmatic approach was
adopted in line with recent evidence [30]. If an item was
missing for HADS sub-scale all other scores for that par-
ticipant were used to impute the mean value for the
missing item [30]. If > 2 items were missing the whole
HADS sub-scale was treated as missing. We examined
associations with missingness using a series of logistic
regressions to inform selection of variables included in
the imputation models [31].
Missing data were handled using multiple imputation
using chained equations (MICE) [32] to impute 50 datasets
[32, 33] with predictive mean matching for continuous data
(supplement 1). HADS scores had an approximately Gauss-
ian distribution and extensive assessment was undertaken
of model specifications for both the imputation and main
analysis models. For example, collinearity was explored
using variance inflation factors, margins, margins plots and
contrasts (data available upon request).
Selection of candidate predictors
Stakeholder involvement highlighted that the potential
list of > 20 predictors would be unwieldly to use in
Harris et al. Journal of Patient-Reported Outcomes           (2020) 4:103 Page 4 of 9clinical practice and unacceptable to patients, so this
needed to be reduced. Traditionally analysts used univari-
ate screening or stepwise regressions to achieve this,
where inclusion of variables in a model is overdependent
on null hypothesis significance testing and based on pre-
determined criteria (e.g. p values) [19]. However, it is now
widely accepted that this should be avoided because it can
lead to poor estimation, is biased in selection and can re-
sult in model overfitting [19, 34]. These weaknesses limit
the generalizability of the resulting regression model when
intended for prediction purposes [21, 35].
Modern regularization techniques provide a powerful
alternative to overcome these problems [21]. In this sec-
ondary analysis Least Absolute Shrinkage and Selection
Operator (LASSO) [36] was used as it produces parsi-
monious models and can help to minimize prediction
error and overfitting by reducing the regression coeffi-
cients. This is achieved by introducing a penalty term
[19, 21, 37] whereby the penalty term is equal to the
sum of the absolute coefficient, meaning all coefficients
are shrunk and some reduce to zero [38]. Those reduced
to zero are effectively removed from the model, making it
a useful tool for developing parsimonious PRM to be used
in clinical practice. To put simply, LASSO introduces
some constraint which prevents the coefficients estimates
having an inappropriately large magnitude [39].
LASSO was implemented for each imputed dataset,
with predictors selected if they were included in ≥50% of
the models [32, 40] or if they were a known predictor
(age, anxiety and depression) [8]. LASSO was performed
for all candidate predictors and again separately for all
candidate predictors plus interactions. The final model’s
predictive performance was internally validated using
Bootstrapping based on MI dataset. By generating a new
sample of data from the original sample this provides es-
timates to account for model overfitting or uncertainty
in the entire model development process [17]. Bootstrap
distribution for the predictors across 1000 results was
compared to those of the original model. Model discrim-
ination was assessed by the explained variance (R2) [19].
All analyses followed recommendations for multivariable
predictive research [17, 35, 41, 42]. To compare with
standard approaches to model development we also built
a model using univariate screening on the complete-case
data, whereby a candidate predictor was included in the
multivariable model if unadjusted p ≤ 0.10 [19]. Data
analysis was performed using Stata (version 15) [43].
Results
There were 1847 people who agreed to participate in the
original study and 1425 returned the initial survey (79%).
The sample included 816 women with breast cancer
who were included in this study, of whom 674 returned
surveys at T1 (Fig. 1).Participant characteristics are presented in Table 1.
Mean age was 58 years (SD 11.51), most were married or
living with a partner (72.5%) and White British (93.6%).
Mean anxiety score was 6.5 (SD 4.2) at T0 and 6.8 (SD
4.34) at T1.
Predictive risk model of anxiety
From the 20 candidate predictors, five were selected by
LASSO in > 50% of the MI datasets (Fig. 2, supplement
2) [40]. When examining the LASSO including add-
itional interactions, two additional predictors were se-
lected (financial strain and working status; working
status and homeownership), however, inclusion of these
did not improve model performance and so the parsimo-
nious five predictor model was chosen (not presented
but available on request).
The final model predicted that T1 anxiety scores are
higher with increasing scores on T0 HADS-A, HADS-D
and having caring responsibilities but decrease with
older age and being a homeowner (Table 2). The final
model explained 60% variance in the data. Bootstrap
validation results suggest the level of bias for the final
model was low (− 0.006 to 0.002%, Table 2), indicat-
ing stable accuracy of the estimate between the ori-
ginal and bootstrap samples. In comparison the
univariate screening approach resulted in the inclu-
sion of ten predictors (age, living alone, caring re-
sponsibilities, homeowner, financial need, employment
status, lack of energy/fatigue, feeling unwell, HADS-A,
HADS-D) and explained 59% of variance in the data
(supplement 3).
Discussion
This study developed a parsimonious PRM for anxiety
6-months following breast cancer treatment completion,
using LASSO regression to identify the most salient pre-
dictors. Few studies have attempted to develop multivar-
iable predictive risk models for patient reported anxiety
breast cancer treatment [8]. Anxiety at the end of treat-
ment was an important predictor of anxiety 6-months
later, a finding that is supported by previous research [8]
and policy [16]. In this study we used HADS-A, but
other screening tools can be used in practice with simi-
lar performance [35, 36]. Good screening tools are typic-
ally quick to administer, for example HADS takes 2–5
min to complete [37], and advances in digital data col-
lection mean this can be linked with other important
predictive data in real-time.
In psycho-oncology existing models of outcomes tend
to be explanatory, attempting to elucidate causal mecha-
nisms. Here the goal was prediction and so we used a
data driven approach. We intended the model to be
practical; for it to be useful in clinical practice it needed
to include variables that are either routinely collected or
Fig. 1 Flow chart of participants’ study inclusion. T0, baseline (at the end of treatment); T1, 6 months after baseline
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In contrast, the model built using traditional univariate
screening resulted in twice the number of predictors be-
ing including in the model and would require greater
clinical effort and resource to collect.Fig. 2 Number of times candidate predictors were selected by LASSO in MWe found LASSO regression, increasingly used in ma-
chine learning and precision medicine but rare in psycho-
oncology, was a helpful method to identify predictors and
multiple imputation enabled us to fully utilize the dataset.
We would encourage wider use of robust statisticalI datasets (m = 50)
Table 2 Prediction model estimates and bootstrap estimates
Predictor MI estimate MI bootstrap estimate
B SE 95% CI Bb SEb Z Bias B 95% CI
HADS-A 0.734 0.034 0.67,0.80 0.734 0.027 27.12a 0.000 0.68, 0.79
HADS-D 0.094 0.043 0.01, 0.18 0.095 0.041 2.28b 0.001 0.02, 0.18
Age −0.011 0.011 −0.03, 0.01 −0.010 0.008 −1.30 0.001 − 0.03, 0.01
Caring responsibility 0.485 0.274 −0.05, 1.03 0.488 0.200 2.43a 0.002 0.08, 0.87
Homeowner −0.426 0.326 −1.07, 0.22 −0.432 0.263 −1.62 −0.006 −0.95, 0.08
Constant 2.515 0.793 0.95, 4.08 2.475 0.587 4.28b −0.040 1.39, 3.67
MI estimate: B = MI observed coefficient, SE B = standard error of B, 95% CI (confidence intervals)
MI Bootstrap estimate: Bb = MI bootstrap estimates of coefficient, SEb = standard error of Bb, z = bootstrap estimate divided by the standard error, bias = bias for
the parameter estimate, B 95% CI = bias corrected 95% CI
All estimates are based on MI data (M = 50) and Bootstrap distribution across 1000 results (10,000 random samples with replacement) ap < 0.05 b p < =0.001
Simple 6-month predicted anxiety = 2.5 + (HADS-A score × 0.7) + (HADS-D score × 0.1) + (age x − 0.1) + 0.4(if carer) + − 0.4(if homeowner)
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for psychological outcomes in medicine. LASSO allowed
us to identify the most relevant predictors of anxiety at
follow-up and develop a parsimonious PRM.
An important aspect of predictive rather than ex-
planatory modelling is that variables included in risk
models will not necessarily be individually statistically
significant [21]. However, they may still be important
to include to fine-tune performance as the aim is not
hypothesis testing [19]. Thus, they can have clinical
significance even in the absence of statistical signifi-
cance. Younger age was identified as a possible pre-
dictor of anxiety after treatment finished in previous
research [8]. Although only weakly associated here,
age was still selected by the LASSO procedure. Social
risk factors, although generally thought to be predict-
ive of anxiety for people with other chronic health
conditions [44], have not been consistently identified in
BCS [8]; using LASSO the small but important effects of
social factors helped us refine the model. Housing tenure
and having caring responsibilities have not been identified
as predictors in previous research and it may be that spe-
cific predictors are more relevant to certain social, eco-
nomic and cultural contexts. For example, in the UK
homeownership may serve as a proxy for social economic
status but may not be an important predictor in locations
where renting is more widespread. Further, the definition
of caring responsibility was quite broad as it could include
any caring for an adult or child. Future research is needed
to determine if it is caring per se, or whether it is responsi-
bility for an adult, child or both that is important. There is
some evidence that the risk of anxiety is greater during
chemotherapy treatment than other treatment modalities
[45]. However, in line with previous research [8], chemo-
therapy did not predict anxiety after treatment comple-
tion. This finding is an important message for patients
and clinicians.Limitations
This study was limited to secondary analysis of a pre-
existing data. Longitudinal research is expensive and
funding scarce, so it is generally recognized that there is
a need to use existing datasets for predictive modelling
[46] and that data should ideally be observational and
comprehensive, as with the current study. Nonetheless,
there may be other important variables (lifestyle factors,
newer treatments and adverse-events) not measured in
primary research that may impact on anxiety. Indeed,
these could be important candidate predictors to con-
sider in future research to account for the variance un-
explained in the model. However, this study completes
the first stage in a development process that we will
build upon in future model validation studies. Further-
more, a third of chemotherapy treatment data was miss-
ing which may present some reporting bias although we
attempted to mitigate this using MICE. It was an advan-
tage that this study used data that is widely collected
and a tool that is well understood by clinicians and
researchers.
The original research was conducted with a sample of
women with early stage disease and good oncological
prognosis. Results may be different for women with later
stage disease, many of whom will live for many years with
incurable disease. Further research is needed to determine
predictors in this group. The study sample was limited to
include only women who could read English and future
research is needed to examine its predictive performance
in across the diverse communities in the UK and its utility
in international clinical contexts. Indeed, these issues have
been noted as limitations of well-known PRM in cancer
such as ‘Adjuvant’ and MammaPrint’ [47].
To maintain predictive sensitivity the model was devel-
oped using a continuous outcome making immediate clin-
ical interpretation less straightforward than if a model
with a dichotomous outcome had been developed.
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the early stage of evidence in this area and to make the
model more sensitive. Further, digital technologies allow
greater ease of use and interpretation of such outcomes.
Another limitation was the preliminary nature of this
study and the PRM requires validation in an external sam-
ple with decision-curve analysis to determine the clinical
impact of different thresholds [48]. Validation of this
model in external samples will help us to identify individ-
uals at low, moderate or high risk of anxiety after treat-
ment completion, through calculation of risk scores/
algorithms, ready for translation into a digital tool and
evaluation of clinical implementation in future research.
High quality longitudinal data from similar cohorts is ex-
pensive to collect and currently scarce, therefore we plan
to undertake secondary analysis of trials using PROs to
further refine and externally validate the model.
Future research is needed to determine appropriate
cut-offs based on best practice regarding predictive ac-
curacy and clinical utility [21], and whether standard
HADS-A thresholds are appropriate for this population
[24] and adaptions using different outcome measures.
For example, by examining the utility of different screen-
ing tools where it might be possible to calibrate and
adapt PRM depending on the preferred instrument
already used in clinical setting. Long-term such tools
may help health services plan their resourcing and
provision of follow-up care according to patient charac-
teristics, permitting stratified follow-up with different
support options for different levels of risk.
A strength of this study was the modelling strategy, it
followed recommendations to limit bias in the identifica-
tion of predictors. For example, in many studies model
building procedures such as variable selection is under-
taken on complete-case datasets, even where MI has been
used. Current guidelines do not support this approach as
the results can be biased and lack power [32, 40].
Conclusions
A myriad of individual predictors of anxiety for breast
cancer survivors have been identified in previous re-
search. It is impractical and unnecessary for these all to
be collected and entered into a digital PRM in clinical
practice by busy specialist cancer nurses or oncologists
often responsible for referring to supportive or specialist
psycho-oncology services. Further, previous research has
not used sophisticated statistical learning approaches
now recommended for developing PRM. This study de-
veloped a parsimonious PRM for anxiety after breast
cancer treatment that, if further validated and refined,
has the potential to be adapted to a digital tool to be
used in clinical practice. At completion of treatment
anxiety, depression and having caring responsibilities in-
creased risk for anxiety, whereas being older and owninga home were protective. The methods presented here
may provide a useful framework for others wanting to
harness the power of data driven predictive models for
psychological patient reported outcomes in clinical pop-
ulations. PRMs present the opportunity to facilitate the
use of routinely collected patient reported predictors
and outcomes to enhance patient quality of life through
stratified supportive care packages.Supplementary information
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